The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | S | Sensory organs | |
2 | S01 | Ophthalmologicals | |
3 | S01E | Antiglaucoma preparations and miotics | |
4 | S01EC | Carbonic anhydrase inhibitors | |
5 | S01EC01 | Acetazolamide |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
Route | Amount |
---|---|
ORAL - Oral | 0.75 g |
PAREN - Parenteral | 0.75 g |
Active Ingredient | Description | |
---|---|---|
Acetazolamide |
Acetazolamide is an enzyme inhibitor which acts specifically on carbonic anhydrase. By inhibiting the reaction catalysed by this enzyme in the renal tubules, acetazolamide increases the excretion of bicarbonate and of cations, chiefly sodium and potassium, and so promotes alkaline diuresis. By inhibiting carbonic anhydrase in the eye acetazolamide decreases intra-ocular pressure and is therefore useful in the treatment of glaucoma. |
Title | Information Source | Document Type | |
---|---|---|---|
DIAMOX Sodium Powder for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
DIAMOX SR Capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
DIAMOX Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.